[{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pioneering Medicines, an Initiative of Flagship Pioneering, Establishes First-of-its-Kind Partnership with Cystic Fibrosis Foundation to Develop Breakthrough Treatments for CF","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novo Nordisk and Flagship Pioneering Announce a Strategic Collaboration to Create a Portfolio of Transformational Medicines","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Evelo Biosciences","pharmaFlowCategory":"D","amount":"$79.2 million","upfrontCash":"Undisclosed","newsHeadline":"Evelo Biosciences Announces $79.2 Million Registered Direct Offering of Common Stock","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Syros Pharmaceuticals","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Senda Biosciences","pharmaFlowCategory":"D","amount":"$123.0 million","upfrontCash":"Undisclosed","newsHeadline":"Senda Biosciences Announces Close of $123 Million Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Cellarity","pharmaFlowCategory":"D","amount":"$274.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cellarity Announces Close of $121 Million Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Charles River and Flagship\u2019s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Technology","graph2":"Discovery"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Metaphore Biotechnologies","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Empress Therapeutics","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Evelo Biosciences","pharmaFlowCategory":"D","amount":"$25.5 million","upfrontCash":"Undisclosed","newsHeadline":"Evelo Biosciences Closes $25.5 Million Private Placement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Alltrna","pharmaFlowCategory":"D","amount":"$109.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alltrna Announces Series B Raise of $109 Million to Advance tRNA Medicines for Stop Codon Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform"}]
Find Clinical Drug Pipeline Developments & Deals by Flagship Pioneering
The financing will be used to advance the company's platform and first drug candidates towards the clinic for a first indication in Stop Codon Disease.
The company intends to use the net proceeds to fund the completion of the Company’s ongoing Phase 2a trial of EDP2939, an investigational orally delivered and gut-restricted bacterial extracellular vesicle being developed for the treatment of moderate psoriasis.
The net proceeds will be used to support the development of Empress's proprietary Chemilogics™ product platform which creates potential small molecule medicines and the company's initial pipeline of drug candidates.
The proceeds will advance Metaphore's MIMiC drug discovery platform and build its pipeline for autoimmune, metabolic or oncology indications. The MIMiC™ platform drives unprecedented insights into molecular interactions to design new biomolecules for therapeutic benefit.
Under the agreement, Logica, an offering from Charles River and Valo Health will be deployed by Pioneering Medicines across a portfolio of targets with the aim of creating optimized small molecules that lead to novel therapies for unmet medical needs.
The proceeds of the financing will be used to grow Cellarity’s talent base, strengthen its platform, and advance its pipeline toward the clinic with the development of compounds that have been validated in vitro and in vivo, including in higher species.
The proceeds of the financing will be used to drive further development of Senda’s proprietary programmable medicines platform and advance its first programs into clinical testing. Senda is developing a new class of SendRNA™ medicines.
Net proceeds are expected to be used to advance Syros’ clinical development pipeline including SY-2101, a novel oral form of arsenic trioxide, business development activities, working capital and other general corporate purposes.
Evelo intends to use the net proceeds from the offering to continue the development of EDP1815 in a Phase 2 trial in atopic dermatitis; prepare to advance EDP1815 in registration trials in psoriasis and, upon receipt of positive Phase 2 data, atopic dermatitis.
Novo Nordisk will provide funding for initiated research programmes and have an exclusive option to license each program. The ambition is to initiate three to five research programs within the first three years of the collaboration.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
